In Vitro and in Silico Studies of Potential Coronavirus-Specific 3C-Like Protease Inhibitors

Chem Pharm Bull (Tokyo). 2022 Mar 1;70(3):195-198. doi: 10.1248/cpb.c21-01002. Epub 2021 Dec 25.

Abstract

We investigated similar compounds to ebselen and tideglusib, which exhibit strong activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), using Molecular ACCess System (MACCS) keys. Four candidate compounds were identified. One of them, phenyl-benzothiazol-3-one, showed coronavirus-specific 3C-like (3CL) protease inhibitory activity. The results indicated that a similarity score above 0.81 is a good indicator of activity for ebselen-and-tideglusib-like compounds. Subsequently, we simulated the ring-cleavage Michael reaction of ebselen at the Se center, which is responsible for its 3CL protease inhibitory activity, and determined the activation free energy of the reaction. The results showed that reaction simulation is a useful tool for estimating the activity of inhibitory compounds that undergo Michael addition reactions with the relevant cysteine S atom of 3CL proteases.

Keywords: 3C-like protease; ebselen; molecular modeling; phenyl-benzothiazol-3-one; severe acute respiratory syndrome coronavirus 2.

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • COVID-19 Drug Treatment*
  • Humans
  • Protease Inhibitors* / pharmacology
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Protease Inhibitors